ECG Residuum Signal Averaging for Arrhythmia Risk Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for arrhythmia risk assessment using electrocardiograms (ECGs) face challenges in detecting subtle microvolt-level changes associated with lethal cardiac arrhythmias due to intrinsic morphology differences and signal cancellations, making it difficult to reliably identify life-threatening conditions.
Innovation Solution
A high-throughput method involving the generation of median beat signals from spatially separated ECG leads, calculation of residuum signals, and averaging these to quantify R-wave and T-wave heterogeneity, which helps in identifying arrhythmia risk and myocardial ischemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard ECG leads are used to detect arrhythmia risk, then the method is simple and widely applicable, but the measurement precision is poor due to intrinsic morphology differences and signal cancellations masking microvolt-level changes
Solution Approach 1:
The patent segments the ECG analysis by separating the detection task into multiple components: identifying QRS complexes, extracting T-wave segments, calculating morphology variations across different leads, and computing heterogeneity metrics. This segmentation allows precise measurement of microvolt-level changes while managing complexity through structured processing steps.
Solution Approach 2:
The patent introduces an intermediary processing layer that calculates residuum signals by subtracting the median ECG waveform from individual lead waveforms. This intermediary step eliminates intrinsic morphology differences and signal cancellations, enabling precise detection of microvolt-level arrhythmia-related changes that would otherwise be masked in standard ECG leads.
2Measurement precision
If multiple ECG leads are analyzed to improve detection accuracy, then the measurement precision improves, but the processing time and computational complexity increase
Solution Approach 1:
The patent performs preliminary actions by pre-calculating the median ECG waveform from multiple leads and storing it for subsequent comparisons. This preliminary computation enables rapid calculation of residuum signals during actual arrhythmia detection, improving accuracy through multi-lead analysis while minimizing processing time by avoiding repeated median calculations.
Solution Approach 2:
The patent merges the analysis of multiple ECG leads into a unified heterogeneity metric that quantifies T-wave morphology variations across leads simultaneously. This merging approach improves arrhythmia detection accuracy by capturing spatial distribution of abnormalities while reducing processing time compared to analyzing each lead separately.
3Measurement precision
If detailed ECG morphology analysis is performed to detect subtle changes, then the measurement precision improves, but the ease of operation decreases due to complex signal processing requirements
Solution Approach 1:
The patent implements self-service by having the system automatically calculate the median ECG waveform, extract T-wave segments, compute residuum signals, and generate heterogeneity metrics without requiring manual intervention. This automation maintains high measurement precision for subtle morphology changes while significantly improving ease of operation by eliminating complex manual signal processing requirements.
Solution Approach 2:
The patent transforms the analysis from direct examination of raw ECG waveforms to examination of derived parameters including residuum signals and heterogeneity metrics. This parameter transformation simplifies the operational complexity by providing standardized, interpretable outputs that directly indicate arrhythmia risk while preserving the ability to detect subtle morphology changes through quantitative metrics.
Data Source
AI summary
A method and system for high-throughput prediction of the onset of heart arrhythmias observes trends in abnormal or pathologic morphology of the electrocardiogram (ECG). A first set of ECG signals is monitored from a patient. A baseline measurement is generated from the monitored first set of ECG signals to contain nonpathologic ECG morphologies in each lead. A second set of ECG signals is monitored from the patient and a second baseline measurement is generated from the second set of ECG signals. A residuum signal is generated for each lead based on the baseline measurement and the second baseline measurement. The residuum signals are averaged across the leads. R-wave heterogeneity, T-wave heterogeneity, P-wave heterogeneity, or ST-segment heterogeneity or other indicators of arrhythmia risk or myocardial ischemia are quantified based on the generated residuum signals and the averaged residuum signal.